Cargando…
DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkh...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165142/ http://dx.doi.org/10.1093/neuonc/noac079.076 |
_version_ | 1784720319124078592 |
---|---|
author | Tsai, Jessica W Cejas, Paloma Wang, Dayle K Patel, Smruti Wu, David W Arounleut, Phonepasong Wei, Xin Zhou, Ningxuan Syamala, Sudeepa Dubois, Frank P B Crane, Alexander Pelton, Kristine Vogelzang, Jayne Sousa, Cecilia Baguette, Audrey Chen, Xiaolong Condurat, Alexandra L Dixon-Clarke, Sarah E Zhou, Kevin N Lu, Sophie D Gonzalez, Elizabeth M Chacon, Madison S Digiacomo, Jeromy J Kumbhani, Rushil Novikov, Dana Hunter, J'Ya Tsoli, Maria Ziegler, David S Dirksen, Uta Jager, Natalie Balasubramanian, Gnana Prakash Kramm, Christof M Nathrath, Michaela Bielack, Stefan Baker, Suzanne J Zhang, Jinghui McFarland, James M Getz, Gad Aguet, Francois Jabado, Nada Witt, Olaf Pfister, Stefan M Ligon, Keith L Kleinman, Claudia L Long, Henry Jones, David T W Bandopadhayay, Pratiti Phoenix, Timothy N |
author_facet | Tsai, Jessica W Cejas, Paloma Wang, Dayle K Patel, Smruti Wu, David W Arounleut, Phonepasong Wei, Xin Zhou, Ningxuan Syamala, Sudeepa Dubois, Frank P B Crane, Alexander Pelton, Kristine Vogelzang, Jayne Sousa, Cecilia Baguette, Audrey Chen, Xiaolong Condurat, Alexandra L Dixon-Clarke, Sarah E Zhou, Kevin N Lu, Sophie D Gonzalez, Elizabeth M Chacon, Madison S Digiacomo, Jeromy J Kumbhani, Rushil Novikov, Dana Hunter, J'Ya Tsoli, Maria Ziegler, David S Dirksen, Uta Jager, Natalie Balasubramanian, Gnana Prakash Kramm, Christof M Nathrath, Michaela Bielack, Stefan Baker, Suzanne J Zhang, Jinghui McFarland, James M Getz, Gad Aguet, Francois Jabado, Nada Witt, Olaf Pfister, Stefan M Ligon, Keith L Kleinman, Claudia L Long, Henry Jones, David T W Bandopadhayay, Pratiti Phoenix, Timothy N |
author_sort | Tsai, Jessica W |
collection | PubMed |
description | BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkhead Box R2 (FOXR2) has been identified as a candidate structural variant (SV) driver in a subset of pediatric cancers including CNS embryonal tumors and peripheral neuroblastoma. While FOXR2 has been shown to stabilize MYC isoforms, the mechanistic details through which it enhances tumor formation, other non-SV mechanisms of activating aberrant expression, and the true extent of its role as an oncogene across all cancers have not been systematically evaluated. METHODS: We applied an integrative approach using transcriptomics, epigenetics, in vitro cancer models, and in vivo mouse models to systematically evaluate the mechanisms by which FOXR2 is activated across human cancers. RESULTS: We performed a pan-cancer analysis of FOXR2 activation across over 10,000 adult and pediatric cancer samples, and surprisingly found FOXR2 to be aberrantly upregulated in 70% of all cancer types (including diffuse midline gliomas), and 8% of all individual tumors. FOXR2 expression occurred predominantly in the absence of rearrangement/fusions, single nucleotide variants, or copy number aberrations at the DNA level. Transcriptomic and epigenomic analyses show the vast majority of tumors (78%) aberrantly express FOXR2 through a previously undescribed epigenetic mechanism via hypomethylation of a novel promoter. Using both in vitro and in vivo models, we demonstrate that FOXR2 expression is both sufficient and necessary for transformation across multiple lineages, including DMGs. CONCLUSION: Taken together, this study demonstrates that FOXR2 is a novel and potent oncogene across pediatric and adult cancers, and highlights a new epigenetic mechanism by which its expression is activated. |
format | Online Article Text |
id | pubmed-9165142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91651422022-06-05 DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers Tsai, Jessica W Cejas, Paloma Wang, Dayle K Patel, Smruti Wu, David W Arounleut, Phonepasong Wei, Xin Zhou, Ningxuan Syamala, Sudeepa Dubois, Frank P B Crane, Alexander Pelton, Kristine Vogelzang, Jayne Sousa, Cecilia Baguette, Audrey Chen, Xiaolong Condurat, Alexandra L Dixon-Clarke, Sarah E Zhou, Kevin N Lu, Sophie D Gonzalez, Elizabeth M Chacon, Madison S Digiacomo, Jeromy J Kumbhani, Rushil Novikov, Dana Hunter, J'Ya Tsoli, Maria Ziegler, David S Dirksen, Uta Jager, Natalie Balasubramanian, Gnana Prakash Kramm, Christof M Nathrath, Michaela Bielack, Stefan Baker, Suzanne J Zhang, Jinghui McFarland, James M Getz, Gad Aguet, Francois Jabado, Nada Witt, Olaf Pfister, Stefan M Ligon, Keith L Kleinman, Claudia L Long, Henry Jones, David T W Bandopadhayay, Pratiti Phoenix, Timothy N Neuro Oncol Diffuse Midline Glioma/DIPG BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkhead Box R2 (FOXR2) has been identified as a candidate structural variant (SV) driver in a subset of pediatric cancers including CNS embryonal tumors and peripheral neuroblastoma. While FOXR2 has been shown to stabilize MYC isoforms, the mechanistic details through which it enhances tumor formation, other non-SV mechanisms of activating aberrant expression, and the true extent of its role as an oncogene across all cancers have not been systematically evaluated. METHODS: We applied an integrative approach using transcriptomics, epigenetics, in vitro cancer models, and in vivo mouse models to systematically evaluate the mechanisms by which FOXR2 is activated across human cancers. RESULTS: We performed a pan-cancer analysis of FOXR2 activation across over 10,000 adult and pediatric cancer samples, and surprisingly found FOXR2 to be aberrantly upregulated in 70% of all cancer types (including diffuse midline gliomas), and 8% of all individual tumors. FOXR2 expression occurred predominantly in the absence of rearrangement/fusions, single nucleotide variants, or copy number aberrations at the DNA level. Transcriptomic and epigenomic analyses show the vast majority of tumors (78%) aberrantly express FOXR2 through a previously undescribed epigenetic mechanism via hypomethylation of a novel promoter. Using both in vitro and in vivo models, we demonstrate that FOXR2 expression is both sufficient and necessary for transformation across multiple lineages, including DMGs. CONCLUSION: Taken together, this study demonstrates that FOXR2 is a novel and potent oncogene across pediatric and adult cancers, and highlights a new epigenetic mechanism by which its expression is activated. Oxford University Press 2022-06-03 /pmc/articles/PMC9165142/ http://dx.doi.org/10.1093/neuonc/noac079.076 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Diffuse Midline Glioma/DIPG Tsai, Jessica W Cejas, Paloma Wang, Dayle K Patel, Smruti Wu, David W Arounleut, Phonepasong Wei, Xin Zhou, Ningxuan Syamala, Sudeepa Dubois, Frank P B Crane, Alexander Pelton, Kristine Vogelzang, Jayne Sousa, Cecilia Baguette, Audrey Chen, Xiaolong Condurat, Alexandra L Dixon-Clarke, Sarah E Zhou, Kevin N Lu, Sophie D Gonzalez, Elizabeth M Chacon, Madison S Digiacomo, Jeromy J Kumbhani, Rushil Novikov, Dana Hunter, J'Ya Tsoli, Maria Ziegler, David S Dirksen, Uta Jager, Natalie Balasubramanian, Gnana Prakash Kramm, Christof M Nathrath, Michaela Bielack, Stefan Baker, Suzanne J Zhang, Jinghui McFarland, James M Getz, Gad Aguet, Francois Jabado, Nada Witt, Olaf Pfister, Stefan M Ligon, Keith L Kleinman, Claudia L Long, Henry Jones, David T W Bandopadhayay, Pratiti Phoenix, Timothy N DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title | DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title_full | DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title_fullStr | DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title_full_unstemmed | DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title_short | DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers |
title_sort | dipg-19. foxr2 is an oncogenic driver across pediatric and adult cancers |
topic | Diffuse Midline Glioma/DIPG |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165142/ http://dx.doi.org/10.1093/neuonc/noac079.076 |
work_keys_str_mv | AT tsaijessicaw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT cejaspaloma dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT wangdaylek dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT patelsmruti dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT wudavidw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT arounleutphonepasong dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT weixin dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT zhouningxuan dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT syamalasudeepa dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT duboisfrankpb dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT cranealexander dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT peltonkristine dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT vogelzangjayne dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT sousacecilia dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT baguetteaudrey dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT chenxiaolong dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT conduratalexandral dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT dixonclarkesarahe dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT zhoukevinn dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT lusophied dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT gonzalezelizabethm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT chaconmadisons dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT digiacomojeromyj dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT kumbhanirushil dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT novikovdana dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT hunterjya dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT tsolimaria dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT zieglerdavids dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT dirksenuta dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT jagernatalie dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT balasubramaniangnanaprakash dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT krammchristofm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT nathrathmichaela dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT bielackstefan dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT bakersuzannej dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT zhangjinghui dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT mcfarlandjamesm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT getzgad dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT aguetfrancois dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT jabadonada dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT wittolaf dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT pfisterstefanm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT ligonkeithl dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT kleinmanclaudial dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT longhenry dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT jonesdavidtw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT bandopadhayaypratiti dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers AT phoenixtimothyn dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers |